We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BioMarin announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the company’s Marketing Authorization Application (MAA) for Brineura (cerliponase alfa) to treat children with Neuronal Ceroid Lipofuscino
INSIGHTEC congratulates Nicklaus Children's Hospital for performing the first focused ultrasound procedure on a 21-year old patient suffering seizures associated with a benign hypothalamic hamartoma brain tumor.